(Q37895702)

24 August 2017

1 reference

title

Antipsychotic-induced hyperprolactinaemia (English)

1 reference

24 August 2017

1

Warrick J Inder

1 reference

24 August 2017

David Castle

2

1 reference

24 August 2017

publication date

30 June 2011

1 reference

Australian and New Zealand Journal of Psychiatry

24 August 2017

published in

1 reference

24 August 2017

volume

45

1 reference

24 August 2017

issue

10

1 reference

24 August 2017

page(s)

830-837

1 reference

Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Medication-induced hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Increased serum prolactin after administration of synthetic thyrotropin releasing hormone (TRH) in man

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Role of vasoactive intestinal polypeptide (VIP) in regulating the pituitary function in man

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

A prolactin-releasing peptide in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Transient increase in prolactin secretion following hypothalamo-pituitary disconnection in ewes during anoestrus and the breeding season

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Hyperprolactinaemia in males: a heterogeneous disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Hyperprolactinaemia as an adverse effect in regulatory and clinical toxicology: role in breast and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

The risk for breast cancer is not evidently increased in women with hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Schizophrenia and breast cancer incidence: a systematic review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

A review of the association between antipsychotic use and hyperprolactinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

The impact of hyperprolactinaemia on sexual function in patients with psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Prolactin levels and erectile function in patients treated with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Reducing fracture risk with calcium and vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Difficulties in the medical treatment of prolactinoma in a patient with schizophrenia--a case report with a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Hyperprolactinemia and possibly related development of prolactinoma during amisulpride treatment; three cases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Atypical antipsychotics and pituitary tumors: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Switch to quetiapine in antipsychotic agent-related hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Dose-Dependent Effects of Adjunctive Treatment With Aripiprazole on Hyperprolactinemia Induced by Risperidone in Female Patients With Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Appropriate use of estrogen replacement therapy in adolescents and young adults with Turner syndrome and hypopituitarism in light of the Women's Health Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Estrogen - a potential treatment for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Estrogen in severe mental illness: a potential new treatment approach

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Effect of bromocriptine mesylate on induced hyperprolactinemia in stabilized psychiatric outpatients undergoing neuroleptic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Cabergoline-induced psychotic exacerbation in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

Sexual dysfunction in patients taking conventional antipsychotic medication

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F00048674.2011.589044

10.3109/00048674.2011.589044

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference